Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Industry Analysis & Outlook (2018-2025)

February 2018 •
80 pages •
Report ID: 5339937 •
Format: PDF

Summary
Table of contents
Search Inside

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase.

It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts. However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.

The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc. are being profiled along with their key financials and strategies for growth.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

FAQ

Testimonials

The market research advisor answered my questions quickly and professionally. ReportBuyer's team did their best to ensure that I felt comfortable before making the investment to purchase the report.

Cristian Nunez

Director of Corporate Development Chugach Alaska Corporation

My overall experience with ReportBuyer today has been very positive, and I must thank you for your patience (...). Also, the sample you sent me and the explanations provided were very helpful.

D. Lescuyer

Executive Vice President Oral Business at Skyepharma

The research specialist was very helpful, and proposed the best content for my needs. ReportBuyer also offered a great follow-up, thanks for everything !

P. Thompson

EMEA Managing Director

We were satisfied with the support that ReportBuyer's team provided. Thanks to their recommendations, the report we purchased provided exactly what we want.

Y. Wang

Business Analyst

We didn't have time to do the research internally, and thanks to ReportBuyer's team we were able to find the appropriate data.

S. Chen

Research Coordinator

I was impressed by the customer service: it was fast, responsive, and 100% professional !

D. Krivan

Market Research Analyst

The research specialist provided prompt and helpful service. He also followed up to ensure I had all the information to deliver my business development plan.

C. Adams

Senior Business Development Manager